• LMO2–LDB1 Signaling in AML: Study Insights

  2026-08-07

  The reference study identifies an LMO2/LDB1 protein complex as a functional driver of acute myeloid leukemia cell proliferation and survival. By combining genetic perturbation, protein interaction analysis, transcriptomics, ChIP-seq, and in vivo experiments, it links LDB1-dependent transcriptional regulation with LMO2-mediated AML progression.

• Dietary Arachidonic Acid Accelerates Vaccine-Induced Humoral

  2026-08-07

  This study demonstrates that dietary supplementation of arachidonic acid (ARA) significantly enhances the speed and magnitude of vaccine-induced humoral immunity in both mice and humans. The research uncovers a mechanistic link between ARA-derived lipid mediators and B cell activation, offering new perspectives for nutritional strategies to rapidly boost vaccine efficacy.

• 11β-HSD1 Inhibition Reduces Liver Fibrosis via Notch and NK

  2026-08-06

  This study demonstrates that a novel 11β-HSD1 inhibitor substantially attenuates liver fibrosis in a chronic mouse model by suppressing the Notch signaling pathway and enhancing natural killer cell-mediated clearance of activated hepatic stellate cells. These dual immunometabolic mechanisms highlight new therapeutic avenues for metabolic dysfunction-associated steatotic liver disease (MASLD) and related fibrotic conditions.

• Biodegradable Cationic Polyesters Enable Safer VEGF mRNA Del

  2026-08-06

  A newly engineered three-armed biodegradable polyester with ionization-mimicking cationic lipid properties demonstrates superior VEGF mRNA delivery and angiogenesis in critical limb ischemia models. This innovation addresses toxicity and stability challenges of conventional cationic lipids, offering a safer, dual-functional platform for therapeutic mRNA delivery.

• Fluorescein TSA Fluorescence System Kit: Amplified Sensitivi

  2026-08-05

  Unlock exceptional sensitivity in immunofluorescence with the Fluorescein TSA Fluorescence System Kit. This tyramide-based amplification platform empowers researchers to visualize elusive proteins and transcripts in fixed tissues and cells—where traditional methods fall short.

• Phenytoin in Sodium Channel Modulation: Protocols & Pitfalls

  2026-08-05

  Phenytoin (5,5-diphenylimidazolidine-2,4-dione) is a gold-standard tool for sodium channel modulation research and advanced electrophysiology assays. This article presents stepwise workflows, troubleshooting essentials, and actionable insights for robust neurological disease models—leveraging APExBIO’s high-purity Phenytoin for reproducibility and data integrity.

• Baicalein: Applied Protocols for Cancer and Inflammation Res

  2026-08-04

  Baicalein (5,6,7-trihydroxy-2-phenylchromen-4-one) enables precise inhibition of 12-LOX, empowering researchers to dissect apoptosis and inflammation pathways in cancer models. This article delivers workflow enhancements, troubleshooting insights, and rigorous protocol parameters—bridging advanced mechanistic insights with robust experimental design.

• Tetrahydromagnolol: Applied Workflows for CB2 Receptor Resea

  2026-08-04

  Tetrahydromagnolol, a highly selective peripheral CB2 receptor agonist, enables precise dissection of cannabinoid signaling and anti-inflammatory mechanisms in advanced cellular models. Leveraging recent breakthroughs in GPCR-driven metastasis, this guide details robust protocols, troubleshooting, and comparative insights to maximize research outcomes.

• Amitriptyline HCl (B2231): Protocols and QC for Neuropharmac

  2026-08-03

  Amitriptyline HCl (SKU B2231) is a tricyclic compound designed for precise modulation of serotonin and norepinephrine receptors in neuropharmacology research. It is best suited for assays investigating neurotransmitter receptor function, mood disorder models, and signal transduction pathways. This compound should not be used outside neuropsychiatric or CNS research contexts due to its targeted mechanism and validated specificity.

• DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): App

  2026-08-03

  DIDS is a versatile chloride channel inhibitor, empowering researchers to modulate complex ion transport in cancer, neuroprotection, and vascular studies with precision. This article details optimized workflows, critical troubleshooting, and emerging insights from recent metastasis research, enabling high-impact experimental design with APExBIO’s validated DIDS.

• DPPH Radical: Advanced In Vitro Antioxidant Screening Workfl

  2026-08-02

  DPPH (2,2-Diphenyl-1-Picrylhydrazyl) Radical from APExBIO transforms in vitro antioxidant screening with rapid, reproducible colorimetric workflows. This article details protocol enhancements, real-world troubleshooting, and innovation insights from recent comparative studies—empowering researchers to extract actionable data from natural product extracts and drug candidates.

• Fe3O4@ZIF-8 Nanoparticles: Dual Antibiosis and Osteogenesis

  2026-08-01

  The referenced study presents Fe3O4@ZIF-8 core–shell nanoparticles as a multifunctional solution for jaw osteomyelitis, integrating targeted antibacterial activity with bone regeneration. By leveraging pH-responsive Zn2+ release and superparamagnetic properties, the system addresses persistent infection and bone defect repair, representing a significant step toward translational nanomedicine in infectious bone diseases.

• SNS-032 (BMS-387032): Deep Mechanistic Insights for Precisio

  2026-07-31

  Explore SNS-032 (BMS-387032), a selective CDK2/7/9 inhibitor, through an advanced mechanistic lens. This article uncovers unique cross-domain applications in cancer and viral research, offering protocol guidance and strategic differentiation for scientists.

• Axitinib (AG 013736): Precision Tools for Cancer Biology Res

  2026-07-31

  Axitinib (AG 013736) stands out as a gold-standard selective VEGFR inhibitor for dissecting angiogenesis and tumor growth in advanced cancer research. This article details actionable workflows, protocol parameters, and troubleshooting tips grounded in recent methodological advances, enabling experimental clarity and reproducibility.

• Synthetic DEFB1 mRNA Reduces Cryptosporidium Infection in IE

  2026-07-30

  The reference study demonstrates that transfection of human intestinal cells with synthetic, co-transcriptionally capped DEFB1 mRNA significantly boosts β-defensin 1 expression, resulting in substantial protection against Cryptosporidium parvum infection. This work establishes a foundation for host-directed therapies and highlights the utility of mRNA-based gene induction platforms in anti-parasitic research.

8467 records 3/565 page Previous Next 12345 下5页 Last page